Unmet clinical needs targeted are treatment of wounds in skin and mucosa. For the lead candidate ILP100 in a topical formulation, a first-in-human clinical trial have been completed, EudraCT No. 2019000680-24. With this milestone the Company have significantly de-risked the projects in regulatory, CMC and clinical aspects The clinical phase II programs have already been outlined in interactions with FDA and national regulators in Europe. For wound healing, the objectives are to deliver clinical value by providing cost efficient biological treatments substantially cheaper than traditional biologicals and with better efficacy than medical devices. For treatment of active relapse in inflammatory bowel disease the majority of patients are not responding to treatment with current biologics.